



PRESS RELEASE

CELLMADE AND ITS STRATEGIC PARTNER, THE UNIVERSITY SAVOIE MONT BLANC, ESTABLISHED JOINT LABORATORY FACILITIES DEVELOPING A PERSONALIZED MEDICINE APPROACH DEDICATED TO NASH.

February 2020

CellMade, a biopharmaceutical company actively engaged in the discovery of biomarkers and the development of medical nutrition products for the early diagnosis and preventive treatment of metabolic and inflammatory disease, strengthens its translational research efforts via the establishment of a joint research laboratory with the University Savoie Mont Blanc (USMB).

During the development of its proprietary technology platform, *CellInsight*, CellMade established biomarker discovery projects in parallel to *in vitro* and *ex vivo* screening of active compounds. The identified blood biomarkers measure the progression of metabolic diseases. Non-invasive analysis enables early identification of patients suffering from metabolic disease and allows for monitoring patient's reactivity to treatment schedules.

To further strengthen its innovation efforts, CellMade established joint laboratory facilities with USMB via merging two platforms: *research* and *technological*. Due this structured **public-private cooperation**, CellMade combines several levels of research from the discovery of biomarkers and active compounds up to industrialization and commercialization, thus translating laboratory results into viable market applications.

« *Within the CellMade – USMB case, we are not in a classical cooperation, but in a strong and integrated public-private cooperation merging two platforms: the research platform of USMB and the technology platform of CellMade. This merger allows us to cover all phases of translational research, from basic science to the final diagnostic and therapeutic applications* », said Ronald Bronsaer.

At the basis of this cooperation are networking events organized by the local economic development agency. CellMade has physically integrated the USMB laboratories. Our flex teams work hand-in-hand on long-term projects whilst sharing risk and benefit.

A strong public-private cooperation in response to a major health care problem!

With the uptrend of western-style dietary habits accompanied by an ever-increasing sedentary lifestyle, the number of people suffering from chronic overweight and obesity is continuously rising. *“In France, and for the adult population only, more than 6 million people suffer from obesity and approximately 16 Million people are overweighed. If we don't react now, a real epidemic of Non-Alcoholic Steatohepatitis (NASH) will develop and will generate unprecedented costs for the health care systems within the next 10, 20, 30 years. No public health care system will be able to cover such costs”*, said Ronald Bronsaer. In line with its



PRESS RELEASE

translational research initiatives, CellMade wishes to rethink the current clinical model coupling diagnostic tools and medical nutrition products for early detection and preventive treatment of metabolic diseases.

Our current activity is dedicated to the development of a non-invasive diagnostic tool coupled to a medical nutrition product. CellMade's approach allows for early and preventive management of patients suffering from NASH. Prevention, or at least slowing down the progression, of NASH is potentially the only option to overcome development of associated metabolic diseases such as a Type II Diabetes and cardiovascular disease. As of today, no direct therapeutical treatment for NASH is authorized.

Ronald Bronsaer, Managing Director and Founder of CellMade, said: « Our research cooperation's, in France as well as internationally, allowed us to validate the scientific concept of our proprietary biomarker programs. On short notice, this novel and innovative tool for stratifying NASH patients' populations will be made available to the clinical research community (version 1: for research use only). In parallel, the biomarker signature will be further used within *in vitro* and *ex vivo* screening of active compounds using the *CellInsight* platform. This novel technology should allow CellMade to enter into strategic alliances with major players in the field of metabolic diseases ».

About CellMade: A Biopharmaceutical company studying metabolic dysfunction at the basis of widespread diseases such as obesity, non-alcoholic fatty liver disease, type II diabetes and cardiovascular diseases. CellMade and its scientific cooperation's identify new biomarkers and therapeutic targets and develop a comprehensive range of medical nutrition products. The current biomarker and medical nutrition development projects focus on early diagnosis and preventive treatment of NASH. The Company established joint laboratory facilities with the University Savoie Mont Blanc and is located within the University laboratories at the scientific development campus of Le Bourget-du-Lac (France). The medical nutrition product is a multi-hit approach based upon solid scientific proof. The Company enters into clinical development. The phase I/II and II studies will demonstrate safety and efficacy of CellMade's clinical nutrition product. Finally, the Company will submit application dossiers to regulatory authorities as to obtain the authorization for labelling the clinical nutrition product with strong health claims.

Contact(s) :

www.laboratoire-cellmade.fr

ronald.bronsaer@laboratoire-cellmade.fr

Tel : 04.57.34.53.02